ASH 2019 | 4-year update of MURANO: venR shows sustained PFS and OS benefits versus BR
John Seymour, MBBS, PhD, FRACP, Peter MacCallum Cancer Centre, Melbourne, Australia, presents a 4-year update of the MURANO study (NCT02005471) which has shown durable responses in patients treated with venetoclax and rituximab (venR) compared to bendamustine and rixutimab (BR). Prof. Seymour discusses an analysis of retreatment as well. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Get great new content delivered to your inboxSign up